ACM
DYN icon

ADAR1 Capital Management’s Dyne Therapeutics DYN Stock Holding History

ADAR1 Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$196K – 318
2025
Q4 		$196K Sell
10,000
-10,000
-50% -$189K 0.01% 230
2025
Q3 		$253K Hold
20,000
– – 0.02% 171
2025
Q2 		$190K Buy
+20,000
New +$220K 0.03% 156

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ADAR1 Capital Management's DYN Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Dyne Therapeutics (DYN) stake by 9.8% in Q2 2026, selling an estimated $86.3K and leaving 42,821 shares worth $951K. The position accounts for 0.04% of the portfolio, ranked #172.

ADAR1 Capital Management first reported a position in DYN in Q1 2024 and has held it in 8 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • ADAR1 Capital Management held 42,821 shares of Dyne Therapeutics worth $951K as of Q2 2026.
  • ADAR1 Capital Management sold 4,642 Dyne Therapeutics shares in Q2 2026, an estimated $86.3K.
  • Dyne Therapeutics made up 0.04% of ADAR1 Capital Management's portfolio in Q2 2026, its #172 holding.
  • ADAR1 Capital Management first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.